Stories

In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a precise moment in his career.

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.

At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level. 

Working in early development, I have the privilege to see the next generation of therapeutic science take shape – and few areas are more compelling than immuno-oncology (I-O). From first data points in the lab to breakthroughs in the clinic, it is clear that we are entering a new era with the potential to deliver transformative outcomes for patients.

Late-stage partnering is unforgiving — high-stakes, capital-intensive, and fiercely competitive. The cost of a poor partnership isn’t just financial; it’s the lost opportunity to advance a program that could have changed patient outcomes but didn’t get the right partner at the right moment.